Production (Stage)
Altamira Therapeutics Ltd.
CYTOF
$0.10
$0.00060.60%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | -- | -11.75% | -11.75% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | 55.81% | 55.81% | -- |
| Total Operating Expenses | -- | -- | 7.16% | 7.16% | -- |
| Operating Income | -- | -- | -7.16% | -7.16% | -- |
| Income Before Tax | -- | -- | 4.07% | 4.07% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | 4.07% | 4.07% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | 27.00% | 27.00% | -- |
| EBIT | -- | -- | -7.16% | -7.16% | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 95.96% | 95.96% | 92.56% | 92.56% | 92.27% |
| Normalized Basic EPS | -- | -- | 90.30% | 90.30% | -- |
| EPS Diluted | 95.96% | 95.96% | 92.56% | 92.56% | 92.27% |
| Normalized Diluted EPS | -- | -- | 90.30% | 90.30% | -- |
| Average Basic Shares Outstanding | 633.54% | -- | 881.29% | 881.29% | 979.78% |
| Average Diluted Shares Outstanding | 633.54% | 1,616.14% | 881.29% | 881.29% | 979.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |